Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT

Nagler A, Labopin M, Tischer J, Raiola AM, Kunadt D, Vydra J, Blaise D, Chiusolo P, Fanin R, Winkler J, Forcade E, Van Gorkom G, Ciceri F, Mohty M (2024)

Publication Language: English

Publication Type: Journal article

Publication year: 2024

Journal

Blood Advances American Society of Hematology

Book Volume: 8

Pages Range: 4223-4233

Journal Issue: 15

DOI: 10.1182/bloodadvances.2024012798

Abstract

We compared the outcomes of haploidentical stem cell transplantation (haplo-HSCT) with posttransplant cyclophosphamide (PTCy) in 719 patients with primary refractory (PR) or first relapse (Rel) secondary acute myeloid leukemia (sAML; n = 129) vs those with de novo AML (n = 590), who received HSCT between 2010 and 2022. A higher percentage of patients with sAML vs de novo AML had PR disease (73.6% vs 58.6%; P = .002). In 81.4% of patients with sAML, the antecedent hematological disorder was myelodysplastic syndrome. Engraftment was 83.5% vs 88.4% in sAML and de novo AML, respectively (P = .13). In multivariate analysis, haplo-HSCT outcomes did not differ significantly between the groups: nonrelapse mortality hazard ratio (HR), 1.38 (95% confidence interval [CI], 0.96-1.98; P = .083), relapse incidence HR, 0.68 (95% CI, 0.4.7.-1.00; P = .051). The HRs for leukemia-free survival, overall survival, and graft-versus-host disease (GVHD)–free, and GVHD and relapse–free survival were 0.99 (95% CI, 0.76-1.28; P = .94), 0.99 (95% CI, 0.77-1.29; P = .97), and 0.99 (95% CI, 0.77-1.27; P = .94), respectively. We conclude that outcomes of haplo-HSCT with PTCy are not different for PR/Rel sAML in comparison with PR/Rel de novo AML, a finding of major clinical importance.

Authors with CRIS profile

Julia Winkler Department of Medicine 5 – Haematology and Oncology

Involved external institutions

Chaim Sheba Medical Center at Tel HaShomer / המרכז הרפואי עש חיים שיבא – תל השומר‎‎ IL Israel (IL) Hôpital Saint-Antoine FR France (FR) Klinikum der Universität München DE Germany (DE) Ospedale Policlinico San Martino IT Italy (IT) Universitätsklinikum Carl Gustav Carus Dresden DE Germany (DE) Fondazione Policlinico Universitario Agostino Gemelli IRCCS IT Italy (IT) Hôpital Haut-Levêque - CHU de Bordeaux FR France (FR) Ospedale San Raffaele (früher: Centro San Raffaele del Monte Tabor Foundation) IT Italy (IT) Institute of Hematology and Blood Transfusion (IHBT) / Ústav hematologie a krevní transfuze (ÚHKT) CZ Czech Republic (CZ) Maastricht University Medical Center (UMC+) NL Netherlands (NL) University Hospital of Udine IT Italy (IT)

How to cite

APA:

Nagler, A., Labopin, M., Tischer, J., Raiola, A.M., Kunadt, D., Vydra, J.,... Mohty, M. (2024). Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT. Blood Advances, 8(15), 4223-4233. https://doi.org/10.1182/bloodadvances.2024012798

MLA:

Nagler, Arnon, et al. "Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT." Blood Advances 8.15 (2024): 4223-4233.

BibTeX: Download